HOUSTON--(BUSINESS WIRE)--Bio-Path Holdings, Inc., a publicly traded biotechnology company with drug development operations in Houston, Texas (symbol OTCBB: BPTH), announced today it has entered into a drug manufacturing agreement with Althea Technologies, Inc. The agreement creates a solid working relationship between the parties for the manufacturing development and current Good Manufacturing Practice (cGMP) manufacture of the Company’s lead novel therapeutic drug liposomal Grb-2. It is expected that the cGMP drug product manufactured by Althea will be used in the Phase I clinical study of liposomal Grb-2 in chronic myelogenous leukemia (CML), and acute myeloid leukemia (AML) which Bio-Path plans to conduct at The University of Texas M. D. Anderson Cancer Center (“M. D. Anderson”).
